MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$8.71 (+11.85%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Mirum Pharmaceuticals, Inc. grew revenue 44.0% to $618.07M over the twelve months to Jun 30, 2026. Free cash flow was -$228.74M, down 2751.5% from a year earlier.
Revenue
$618.07M
+44.0% vs. a year earlier
Operating income
-$833.97M
TTM Q2 2026
Free cash flow
-$228.74M
-2751.5% vs. a year earlier
EPS, diluted
-$14.55
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.21B
- P/E ratio
- –
- Price to sales
- 8.43
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -4.39%
Fundamentals
- Revenue
- $618.07M
- Net income
- -$860.21M
- EPS, diluted
- -$14.55
- Free cash flow
- -$228.74M
- Book value per share
- -$0.16
- Diluted shares
- 63M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$618.07M+44.0% YoY
Operating income
-$833.97M
Net income
-$860.21M
EPS, diluted
-$14.55
Free cash flow
-$228.74M-2751.5% YoY
Reported periodTrailing twelve months